Altogether, these findings demonstrate that the enhanced glycolytic activity exhibited by CD133/PROM1HIGH patient-derived GBM cells corresponds with lower mitochondrial metabolism as compared to CD133/PROM1LOW cells. Here, PROM1 is linked to glioblastoma.